Diwali 2025 Stock Picks: 11 'Buy' Ideas with up to 93% Upside Potential

Prabhudas Lilladher has released its Diwali 2025 stock picks with 10 'Buy' recommendations across large caps, midcaps, and thematic segments. The picks focus on blue-chip consistency and balance sheet resilience, with a target price range of 8.7% to 93% upside potential. Large-cap names include Hindustan Aeronautics, ICICI Bank, ITC, State Bank of India, Apollo Hospitals, and Britannia Industries.

Prabhudas Lilladher has released its Diwali 2025 stock picks, offering 10 'Buy' recommendations across large caps, midcaps, and thematic segments. The picks focus on blue-chip consistency and balance sheet resilience, with target price ranges offering 8.7% to 93% upside potential. The large-cap names include Hindustan Aeronautics, ICICI Bank, ITC, State Bank of India, Apollo Hospitals, and Britannia Industries.

The brokerage's picks reflect earnings stability and valuation comfort amid ongoing market volatility. Hindustan Aeronautics, for instance, is recommended with a target price of Rs 5,500, implying an upside of 15.9%. The company is at the forefront of India's defense modernization, with an order book exceeding Rs 95,000 crore. ICICI Bank, with a target price of Rs 1,730, offers an upside of 25.4%, driven by steady retail and SME lending growth and a robust capital base. ITC, with a target price of Rs 530, is expected to benefit from its FMCG portfolio expansion and strong hotel performance, with an upside of 32.8%.

State Bank of India, with a target price of Rs 960, is expected to sustain double-digit earnings growth driven by healthy loan growth and improved asset quality. Apollo Hospitals, with a target price of Rs 9,300, is expected to see healthy occupancy and patient footfalls, with an 18% upside. Britannia Industries, with a target price of Rs 6,484, is expected to benefit from innovation, cost rationalization, and revival in rural demand, with a 10.5% upside.

The picks also include mid-cap and thematic names such as DOMS Industries and Eris Lifesciences, which are expected to benefit from strong market share gains and chronic therapy focus, respectively. KEI Industries, with a target price of Rs 4,946, is expected to benefit from strong demand from infrastructure, real estate, and exports, with a 14.7% upside.

The brokerage's recommendations are based on a thorough analysis of each company's financial health, market position, and growth prospects. The picks offer a diverse portfolio with significant upside potential, making them attractive for investors seeking to capitalize on the Indian market's growth opportunities.